Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Long-Term Extension Study of Vosoritide in Achondroplasia
2018-004364-66Phase 2Unknown
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vosoritide in achondroplasia (ACH), sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Treatment-emergent adverse events. Status: unknown.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2018-004364-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004364-66.